EUGENE, Ore.--(BUSINESS WIRE)--Cascade Chemistry, a leading contract research and manufacturing organization serving the pharmaceutical, materials, and chemical industries, today announced that it has been selected to produce the active pharmaceutical ingredient (API) for clinical trial supplies of RBT-9, an investigational therapy entering a Phase 2 trial for the treatment of COVID-19 patients who are at high risk of deteriorating health due to age or comorbid conditions such as kidney or cardiovascular disease. RBT-9, which has been awarded Fast Track designation by the U.S. Food and Drug Administration (FDA), has demonstrated both antiviral and immune-modulating activities in preclinical studies.